Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637777 | 0.88 | CA1 (0.35) | CA2CA1CA9 | |
| SCHEMBL10419819 | 0.85 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL28066823 | 0.85 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL7151445 | 0.85 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL1151202 | 0.85 | CA2 (0.35) | CA2CA1CA9 | |
| SCHEMBL24505788 | 0.80 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL15432496 | 0.80 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL12230182 | 0.80 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL24079389 | 0.80 | CA2 (0.47) | CA2CA1CA9 | |
| SCHEMBL18009708 | 0.80 | CA2 (0.47) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | CA2 4481/4885CA1 3914/4885CA9 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.